Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

NCT07085182 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Tislelizumab
Chemotherapy
Hypofractionated Radiotherapy

Interventions

DRUG: SBRT combined with Tislelizumab followed by Tislelizumab

Sponsor

Zibo Municipal Hospital